Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582106 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL12161295 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29351388 | 0.92 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL24709575 | 0.87 | SLC22A6 (0.37) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL3451522 | 0.87 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL16685 | 0.87 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Hydroxyamine SCHEMBL8490496 | 0.85 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL22315777 | 0.84 | PTGS1 (0.50) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29579224 | 0.84 | PTGS1 (0.50) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| Glycine SCHEMBL1694000 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074042-A | Histamine H1 receptor antagonistic composition | 株式会社明治 | 2026-05-22 | — | — | CN | claimed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| CN-119219738-A | Alternaria sinica antihypertensive peptide as well as preparation method and application thereof | 湘潭大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118873503-A | Oral flash-disintegrating tablet of pet milk calcium and preparation method and application thereof | 济南广盛源生物科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-118376786-A | Urine metabolism marker for colorectal cancer detection and application thereof | 哈尔滨脉图精准技术有限公司 | 2024-07-23 | — | — | CN | claimed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | claimed |
| CN-116870184-A | Self-assembled material for improving atherosclerosis as well as preparation method and application thereof | 国家纳米科学中心 | 2023-10-13 | — | — | CN | claimed |
| US-20230272100-A1 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-31 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-112852905-B | Application of dipeptide in improving paramylon content in euglena | 优格天成生物技术(义乌)有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| EP-2207525-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'Oréal (FR) | 2010-07-21 | — | — | EP | claimed |
| EP-2205201-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'Oreal (FR) | 2010-07-14 | — | — | EP | claimed |
| WO-2009053594-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053584-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053587-A2 | COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| EP-2021353-A2 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) | 2009-02-11 | — | — | EP | claimed |
| WO-2007136295-A2 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU 'SIA PEPTIDES' (RU) | 2007-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272100-A1 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | IGLV6-57, CD47, IGSF11 | ALDH1A1 2739/4885LMNA 4598/4885MAPT 3673/4885 |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | ALDH1A1 1901/4885LMNA 1561/4885MAPT 2575/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | ALDH1A1 1510/4885LMNA 833/4885MAPT 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.